Literature DB >> 31003196

Current status of small molecule drug development for Ebola virus and other filoviruses.

Megan R Edwards1, Christopher F Basler2.   

Abstract

The filovirus family includes some of the deadliest viruses known, including Ebola virus and Marburg virus. These viruses cause periodic outbreaks of severe disease that can be spread from person to person, making the filoviruses important public health threats. There remains a need for approved drugs that target all or most members of this virus family. Small molecule inhibitors that target conserved functions hold promise as pan-filovirus therapeutics. To date, compounds that effectively target virus entry, genome replication, gene expression, and virus egress have been described. The most advanced inhibitors are nucleoside analogs that target viral RNA synthesis reactions.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Year:  2019        PMID: 31003196      PMCID: PMC6556423          DOI: 10.1016/j.coviro.2019.03.001

Source DB:  PubMed          Journal:  Curr Opin Virol        ISSN: 1879-6257            Impact factor:   7.090


  132 in total

1.  Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Authors:  John H Connor; Margie O McKenzie; Griffith D Parks; Douglas S Lyles
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

2.  A forward genetic strategy reveals destabilizing mutations in the Ebolavirus glycoprotein that alter its protease dependence during cell entry.

Authors:  Anthony C Wong; Rohini G Sandesara; Nirupama Mulherkar; Sean P Whelan; Kartik Chandran
Journal:  J Virol       Date:  2010-01       Impact factor: 5.103

3.  Ebola virus VP24 proteins inhibit the interaction of NPI-1 subfamily karyopherin alpha proteins with activated STAT1.

Authors:  St Patrick Reid; Charalampos Valmas; Osvaldo Martinez; Freddy Mauricio Sanchez; Christopher F Basler
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Enantiomeric 3-deaza-1',6'-isoneplanocin and its 3-bromo analogue: Synthesis by the Ullmann reaction and their antiviral properties.

Authors:  Chong Liu; Qi Chen; Stewart W Schneller
Journal:  Bioorg Med Chem Lett       Date:  2015-12-19       Impact factor: 2.823

Review 5.  Genetics and Treatment Response in Parkinson's Disease: An Update on Pharmacogenetic Studies.

Authors:  Cristina Politi; Cinzia Ciccacci; Giuseppe Novelli; Paola Borgiani
Journal:  Neuromolecular Med       Date:  2018-01-05       Impact factor: 3.843

6.  Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Authors:  Emily Happy Miller; Gregor Obernosterer; Matthijs Raaben; Andrew S Herbert; Maika S Deffieu; Anuja Krishnan; Esther Ndungo; Rohini G Sandesara; Jan E Carette; Ana I Kuehne; Gordon Ruthel; Suzanne R Pfeffer; John M Dye; Sean P Whelan; Thijn R Brummelkamp; Kartik Chandran
Journal:  EMBO J       Date:  2012-03-06       Impact factor: 11.598

7.  Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors.

Authors:  Clément Grandin; Marianne-Lucas Hourani; Yves L Janin; Daniel Dauzonne; Hélène Munier-Lehmann; Adeline Paturet; Fabrice Taborik; Astrid Vabret; Hugues Contamin; Frédéric Tangy; Pierre-Olivier Vidalain
Journal:  Antiviral Res       Date:  2015-11-22       Impact factor: 5.970

8.  Antiviral and antimetabolic activities of neplanocins.

Authors:  E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1985-07       Impact factor: 5.191

9.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

10.  GSK983: a novel compound with broad-spectrum antiviral activity.

Authors:  Robert Harvey; Kevin Brown; Qin Zhang; Margaret Gartland; Leslie Walton; Christine Talarico; Wendell Lawrence; Dean Selleseth; Neil Coffield; Jeffry Leary; Kelly Moniri; Sara Singer; Jay Strum; Kristjan Gudmundsson; Karen Biron; Karen R Romines; Phiroze Sethna
Journal:  Antiviral Res       Date:  2009-01-31       Impact factor: 5.970

View more
  10 in total

1.  Discovery of Adamantane Carboxamides as Ebola Virus Cell Entry and Glycoprotein Inhibitors.

Authors:  Michael B Plewe; Nadezda V Sokolova; Vidyasagar Reddy Gantla; Eric R Brown; Shibani Naik; Alexandra Fetsko; Donald D Lorimer; David M Dranow; Hayden Smutney; Jameson Bullen; Rana Sidhu; Arshil Master; Junru Wang; E Adam Kallel; Lihong Zhang; Birte Kalveram; Alexander N Freiberg; Greg Henkel; Ken McCormack
Journal:  ACS Med Chem Lett       Date:  2020-05-01       Impact factor: 4.345

2.  A Virion-Based Assay for Glycoprotein Thermostability Reveals Key Determinants of Filovirus Entry and Its Inhibition.

Authors:  Robert H Bortz; Anthony C Wong; Michael G Grodus; Hannah S Recht; Marc C Pulanco; Gorka Lasso; Simon J Anthony; Eva Mittler; Rohit K Jangra; Kartik Chandran
Journal:  J Virol       Date:  2020-08-31       Impact factor: 5.103

3.  Controlling emerging zoonoses at the animal-human interface.

Authors:  Riley O Mummah; Nicole A Hoff; Anne W Rimoin; James O Lloyd-Smith
Journal:  One Health Outlook       Date:  2020-09-18

4.  Identification of filovirus entry inhibitors targeting the endosomal receptor NPC1 binding site.

Authors:  Leah Liu Wang; Nicholas Palermo; Leslie Estrada; Colton Thompson; J J Patten; Manu Anantpadma; Robert A Davey; Shi-Hua Xiang
Journal:  Antiviral Res       Date:  2021-03-08       Impact factor: 5.970

5.  Engineered Human Cathelicidin Antimicrobial Peptides Inhibit Ebola Virus Infection.

Authors:  Yangsheng Yu; Christopher L Cooper; Guangshun Wang; M Jane Morwitzer; Krishna Kota; Julie P Tran; Steven B Bradfute; Yan Liu; Jiayu Shao; Amanda K Zhang; Lindsey G Luo; St Patrick Reid; Steven H Hinrichs; Kaihong Su
Journal:  iScience       Date:  2020-03-22

6.  Editorial overview: Antiviral strategies: Antiviral drug development for single-stranded RNA viruses.

Authors:  Margo A Brinton; Richard K Plemper
Journal:  Curr Opin Virol       Date:  2019-05-29       Impact factor: 7.090

Review 7.  Pathogenicity and virulence of Marburg virus.

Authors:  Mehedy Hasan Abir; Tanjilur Rahman; Ayan Das; Silvia Naznin Etu; Iqbal Hossain Nafiz; Ahmed Rakib; Saikat Mitra; Talha Bin Emran; Kuldeep Dhama; Ariful Islam; Abolghasem Siyadatpanah; Shafi Mahmud; Bonlgee Kim; Mohammad Mahmudul Hassan
Journal:  Virulence       Date:  2022-12       Impact factor: 5.882

Review 8.  Immunomodulatory Role of the Antimicrobial LL-37 Peptide in Autoimmune Diseases and Viral Infections.

Authors:  Bapi Pahar; Stefania Madonna; Arpita Das; Cristina Albanesi; Giampiero Girolomoni
Journal:  Vaccines (Basel)       Date:  2020-09-10

9.  Formulation, Stability, Pharmacokinetic, and Modeling Studies for Tests of Synergistic Combinations of Orally Available Approved Drugs against Ebola Virus In Vivo.

Authors:  Courtney L Finch; Julie Dyall; Shuang Xu; Elizabeth A Nelson; Elena Postnikova; Janie Y Liang; Huanying Zhou; Lisa Evans DeWald; Craig J Thomas; Amy Wang; Xin Xu; Emma Hughes; Patrick J Morris; Jon C Mirsalis; Linh H Nguyen; Maria P Arolfo; Bryan Koci; Michael R Holbrook; Lisa E Hensley; Peter B Jahrling; Connie Schmaljohn; Lisa M Johansen; Gene G Olinger; Joshua T Schiffer; Judith M White
Journal:  Microorganisms       Date:  2021-03-10

10.  Filovirus VP24 Proteins Differentially Regulate RIG-I and MDA5-Dependent Type I and III Interferon Promoter Activation.

Authors:  Felix B He; Hira Khan; Moona Huttunen; Pekka Kolehmainen; Krister Melén; Sari Maljanen; Mengmeng Qu; Miao Jiang; Laura Kakkola; Ilkka Julkunen
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.